You are here:
26 July 2018 / deal

Acquisition of Takeda Chromo by Shanghai Pharmaceuticals Holding Co.

Loyens & Loeff advised Shanghai Pharmaceuticals on the acquisition of Takeda Chromo Beteiligungs AG.

The Belgian ‘Cayman tax’ and its impact on wealth and estate planning in Belgium

Shanghai Pharmaceuticals Holding Co. (Hong Kong) announced the entering into a share purchase agreement with Takeda AG, a wholly-owned subsidiary of Takeda Japan (listed on the Tokyo Stock Exchange) to acquire 100% of the issued and outstanding share capital of Takeda Chromo Beteiligungs AG. Upon completion of the USD 144 million acquisition, Shanghai Pharmaceuticals will increase its direct and indirect shareholding in Techpool Bio-pharma Co., Ltd, a global leader in natural urine protein drugs, to approximately 67,14%. The acquisition is, among other conditions, still subject to approval by the China National Market Supervision Administration.

Loyens & Loeff advised Shanghai Pharmaceuticals Holding Co. as Swiss transaction counsel on this acquisition. The team was led by partner Marco Toni (Corporate / M&A, Switzerland) and consisted of Jana Bieli (Corporate / M&A, Switzerland) and Rebecca Kühne (Tax, Switzerland).

 



(Non-)Equivalence of Swiss Stock Exchanges and Countermeasures

An Overview of (non-)equivalence of Swiss Stock Exchanges and Countermeasures read more

Ranking of L&L Switzerland in the International Tax Review (ITR)

The ITR has published its new rankings. Switzerland is recognized as a top player in the rankings for World Tax and World Transfer Pricing. read more

IFLR1000 Guide 2019 – Ranking of Loyens & Loeff Switzerland

L&L Switzerland is included in the 2019 edition of the IFLR Financial and Corporate Guide for worldwide leading financial and corporate law firms. read more